Ashland opened higher at $77.00, compared with its previous close of $76.72. In the last trading session, the stock traded between $75.46 and $77.45. It showed a downward intraday trend.
An investment of $100 made 5 years ago in Ashland is now worth
$ 74.35
Resulting in a loss of
$ 25.65 (25.65%)
Note: Past profits do not guarantee future returns.
Rating from 5 Analysts
Today's Change
$-1.41 (-1.83%)
Day High
$77.45
Day Low
$75.46
Day Open
$77.00
Prev Close
$76.72
Volume
7,99,730
1W Return
-1.45%
1M Return
6.36%
3M Return
1.00%
6M Return
39.26%
1Y Return
50.45%
Market Cap ($ Mn)
3,449
PE Ratio
47.67
PB Ratio
1.82
PEG Ratio
10.15
ROE
-34.80%
ROCE
-16.28%
EPS (TTM)
$0.35
1 Week
-1.45%
1 Month
6.36%
3 Months
1.00%
6 Months
39.26%
9 Months
20.64%
Wells Fargo raises Ashland price target to $80, maintains equal-weight
Wells Fargo raises Ashland price target from $75 to $80. Analyst Abigail Eberts maintains Equal-Weight rating. Valuation update reflects revised projections for the stock.
3 days agoJP Morgan raises Ashland price target to $82, maintains Overweight rating
JP Morgan raised Ashland's price target from $80 to $82. Analyst Jeffrey Zekauskas maintained an Overweight rating. The revision indicates a modest increase in valuation expectations.
7 days agoAshland Q4FY26 Results: Adjusted EPS misses estimates, guides FY27 sales
Q4 adjusted EPS of $1.12 missed consensus estimate of $1.27. Globalize and Innovate strategies delivered $52 million in incremental sales, beating targets by 50%. Hopewell plant under-absorption cost $17.5 million in FY26, with $5 million carryover into FY27. Fiscal 2027 capex guidance raised to up to $140 million due to pulled-forward debottlenecking projects.
8 days agoAshland to host Innovation Day for analysts and investors
Ashland Inc. hosts Innovation Day webcast on September 17, 2026. Event focuses on Technology Platforms' commercial progress and scalability. CEO Guillermo Novo and CFO William Whitaker among presenters. Live webcast and replay available on Ashland's investor website.
2mo agoAshland launches permexa sodium caprate for oral biologics delivery
Ashland launches permexa sodium caprate for oral peptide and biologic delivery. Product aims to improve powder flow, compressibility, and manufacturing scalability. Targets growing pipeline of GLP-1 agonists and other oral therapeutic candidates. Company reports strong pre-launch engagement with global pharma and CDMO partners. Strategy includes synergies with existing vinyl pyrrolidone and derivatives portfolio.
2mo agoAshland declares $0.42 quarterly dividend for shareholders
Ashland Inc. has declared a quarterly cash dividend of $0.42 per share, payable on September 15, 2026. Shareholders must be registered as of September 1, 2026, to receive the payment. With 45,805,711 shares outstanding as of July 31, 2026, this move highlights the company's continued focus on shareholder returns while maintaining its position in the global additives market.
3mo ago| Stock | LTP | Change % | Market Cap | PE |
|---|---|---|---|---|
| $526.55 | +0.91% | $2,41,730.68M | 31.60 | |
| $307.86 | +0.60% | $86,344.88M | 38.49 | |
| $355.76 | +0.12% | $85,947.35M | 31.78 | |
| $315.18 | +0.94% | $70,186.17M | - | |
| $124.97 | +0.44% | $27,605.87M | 16.41 | |
| $32.54 | +3.37% | $23,555.12M | - | |
| $82.65 | -0.63% | $20,694.82M | 87.08 | |
| $155.61 | -0.81% | $20,623.30M | 36.82 | |
| $62.58 | +3.27% | $20,228.48M | - | |
| $105.78 | -0.05% | $13,490.55M | 20.63 | |
| $95.97 | +1.10% | $11,325.42M | 508.74 | |
| $67.15 | +3.28% | $10,556.72M | 48.15 |
An investment of $100 made 5 years ago in Ashland is now worth
$ 74.35
Resulting in a loss of
$ 25.65 (25.65%)
Note: Past profits do not guarantee future returns.
